BOEHRINGER-INGELHEIM
21.9.2021 14:02:26 CEST | Business Wire | Press release
Boehringer Ingelheim today announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology research to develop the next generation of precision medicines designed to revolutionize cancer treatments. The acquisition will allow Boehringer Ingelheim to access Abexxa’s expertise in targeting cancer-specific proteins that are located inside the cell, rather than those expressed on the cell membrane. This enlarges the pool of potential cancer antigen targets. In particular, Abexxa’s technology could lead to the development of cancer immunotherapies that are effective in a broader range of patients and cancer types.
“The acquisition of Abexxa bolsters our commitment to tumor-antigen discovery and new ways of targeting intracellular antigens. Their cutting-edge know-how and technologies for antigen discovery and novel antibody generation strongly complement the current approaches we have been applying successfully to enable immune-targeting of cancer cells,” said Clive R. Wood, Ph.D., corporate senior vice president and global head of discovery research, Boehringer Ingelheim. “By expanding our portfolio of antibodies binding novel intracellular tumor antigens, we are striving to develop unique and broadly applicable new immunotherapeutic approaches for cancer patients,” added Wood.
Abexxa’s innovative platform unlocks the ability to target intracellular antigens of cancer cells by recognizing their presentation on the cell surface by MHC class 1 molecules. While the Abexxa platform addresses the more common HLA-A2 peptide presentation, the company has developed specific expertise in the nonclassical MHC class 1 molecule HLA-E, which has the potential to impact a broader set of cancer patients’ antigens. More specifically, Abexxa has developed a first-in-class T-cell receptor (TCR)-like antibody that can be used to disrupt the NKG2A:HLA-E immune checkpoint axis in oncology. Abexxa molecules are also being formulated to recruit immune cells targeting HLA-E peptide complexes on tumors.
In 2016, Boehringer Ingelheim’s Venture Fund, the arm of the company that invests in ground-breaking therapeutic and digital health approaches, awarded Abexxa initial investment funding. Later that year, Abexxa won Boehringer Ingelheim’s Innovation Prize, which facilitates business growth and rewards new companies for their dedication to innovation. The prize allowed Abexxa to expand operations into a shared lab space in Cambridge, Massachusetts, to continue its research. Boehringer Ingelheim’s investment in Abexxa demonstrates how the company is seeking to foster innovation across leading biotech communities, including the Dallas-Fort Worth, Texas, area.
“The investment by Boehringer Ingelheim’s Venture Fund in 2016 was a defining moment for Abexxa,” said Debra Wawro Weidanz, co-founder and CEO of Abexxa. “The acquisition by Boehringer Ingelheim allows our team to access the company’s expertise and capabilities in immuno-oncology and antibody development and to have the opportunity to translate Abexxa technology into a clinical asset,” said Jon Weidanz, Ph.D., co-founder and CSO of Abexxa.
This transaction is the latest in a series of strategic acquisitions and collaborations that reinforce Boehringer Ingelheim’s overall oncology strategy, bringing together cancer immunology and cancer cell directed therapies to fight cancer. This strategy has further strengthened Boehringer Ingelheim’s position in oncology through the development of leading assets and robust capabilities in cancer vaccines, oncolytic viruses, T-cell engagers, antibody drug conjugates (ADCs) and myeloid and stromal cell modulators. By combining its world-class in-house research and development with that of highly innovative biotechnology companies like Abexxa, Boehringer Ingelheim is developing innovative cancer immunology therapies and accelerating the delivery of the next generation of cancer treatments.
Learn more about Boehringer Ingelheim’s innovation in oncology here .
The total transaction includes an upfront payment, milestones and other consideration payments. Abexxa will continue to operate in the Arlington, Texas, area as a Boehringer Ingelheim family company, collaborating extensively with the colleagues at Boehringer Ingelheim’s U.S. research site in Ridgefield, Connecticut.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/acquisition-expands-research-cancer-immunology
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005613/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dealroom and NATO Innovation Fund: European Defence, Security & Resilience Startups Smash Record with $8.7B Raised in 202510.2.2026 07:05:00 CET | Press release
The 55% year on year surge was fuelled by late-stage mega rounds, indicating a maturing ecosystem to address NATO’s capability needs.Munich retained its position as Europe's #1 DSR hub, with the UK attracting the most VC funding and Central and Eastern Europe showing the largest growth.AI dominated the sector, underpinning 44% of all DSR funding. An exclusive new report by Dealroom and the NATO Innovation Fund shows that European DSR (Defence, Security and Resilience) startups secured a record $8.7 billion in venture capital in 2025. The surge was fuelled by late-stage mega-rounds to support breakthrough technologies that help address critical capabilities for NATO nations – from freedom of operations & mobility, to awareness and decision making, and the security of critical technologies. Record funding surge powers DSR Startups to meet NATO nations’ most urgent security needs Funding for DSR startups increased by 55% year on year and is nearly four times higher than five years ago. It
4Moving Biotech Announces the Closing of a €12 Million Financing to Advance a First-in-Class DMOAD in Knee Osteoarthritis10.2.2026 06:52:00 CET | Press release
- Funding secured, extending the financial runway to reach a proof-of-concept inflection point - Company’s attractiveness reinforced through the onboarding of new investors 4Moving Biotech (4MB), a clinical-stage biotechnology company and a spin-off of 4P-Pharma, developing a first-in-class disease-modifying osteoarthritis drug (DMOAD) for knee osteoarthritis, today announced the closing of a €12 million financing, completed through a structured and coordinated funding process. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209500141/en/ Francis Berenbaum (Left) Luc Boblet, Revital Rattenbach, Jérôme Vailland (Right) This financing was secured from a pool of private investors and family offices, who chose to reinforce their commitment by investing directly at the subsidiary level in 4MB. The round includes a combination of equity and loans, reflecting a flexible capital structure aligned with long-term value creation. Thi
SBTS and ZIM Connections Bring Travel eSIM to Global Travelers10.2.2026 05:00:00 CET | Press release
New service leverages SoftBank Corp.’s wireless network in Japan SBTS, the joint venture between BTS and SoftBank Corp., and ZIM Connections today announced a strategic partnership to launch a travel eSIM solution, initially focused on inbound and outbound travel into and from Japan. The service is now live and commercially available here, marking the first step in a broader global rollout of multiple travel eSIM offerings. The initial launch is a digital travel eSIM platform developed by ZIM Connections and commercialized by SoftBank Corp. (“SoftBank”), a Japan-based telecommunications and IT operator. It enables travelers to easily search for, purchase, and activate unlimited global eSIM plans through a seamless digital experience. The first phase focuses on travelers visiting Japan as well as Japan-based travelers going abroad, leveraging SoftBank’s network for connectivity in the region. This launch represents a fully commercial market introduction, delivering immediate value to tr
FPT Achieves HITRUST r2 v11.5.1 Certification, Demonstrating the Highest Level of Information Protection Assurance10.2.2026 03:00:00 CET | Press release
FPT, a leading global IT company, announced its in-scope platforms and facilities of FPT Data Center have earned certified status from HITRUST for cybersecurity and information protection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209729954/en/ The scope of the HITRUST r2 v11.5.1 certification includes FPT’s Application Services System, Database System, and Deployment System, all hosted and managed within the FPT Data Center in Hanoi, Vietnam, as well as the data center facility itself. The HITRUST Certification demonstrates that FPT has met requirements defined by leading cybersecurity and regulatory frameworks, confirming that strong controls are in place to protect sensitive data and manage risk effectively. The certification also includes the HITRUST AI Security Certification, which validates that the organization’s AI systems are safeguarded against AI-specific threats such as data poisoning, model inversion, an
SheltonAI Announces Global Expansion, Senior Leadership Appointments, and Accelerated Growth9.2.2026 23:04:00 CET | Press release
SheltonAI, the institutional AI platform for valuation, announced senior executive appointments, major global expansion, and strong growth momentum entering 2026. SheltonAI announced several senior leadership appointments, including: Stephen Can, CSO, previously Executive Chairman & Founder of Blackstone Strategic Partners Peter Song, COO, previously COO of Blackstone Strategic Partners Chris Cooper, CFO, previously Global CFO at Sequoia, SoftBank, & Clearlake Capital Paige Shiring, has been promoted to Director, previously with Thoma Bravo 2026 NY Analyst Class & 10+ Hires in January SheltonAI also plans to open several regional HQs in 2026, including: New YorkSydneyGCC Region, with office lead to be announced later in Feb 2026 The company reported significant momentum entering the year, including 10+ new hires in January and over $1 trillion in incremental assets supported by the platform during the month, driven by new client deployments and expanded mandates. SheltonAI’s platform p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom